Journal: International Ophthalmology

Article Title: Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

doi: 10.1007/s10792-024-03226-2

Figure Lengend Snippet: Best corrected visual acuity (BCVA) and central subfield thickness (CST) at baseline, at the time of switch from intravitreal injections of aflibercept to faricimab, and at the 6 months follow up of faricimab treatment. Data are reported for the entire 100 eyes with diabetic macular edema, for "good visual responders" (with an improvement of ≥ 5 letters from baseline), "poor visual responders" (with an improvement of < 5 letters), "good anatomical responders" (showing any reduction in edema compared to baseline) and "poor anatomical responders" (showing no reduction or worsening of edema compared to baseline)

Article Snippet: Fig. 1 Pooled as well as individual line plots summarizing the changes in BCVA ( A , functional response, P = 0.04) and CST ( B , anatomical response, P < 0.001) in study subjects When stratified by best-corrected visual acuity (BCVA) outcomes, only individuals with suboptimal visual responses demonstrated a meaningful increase in BCVA subsequent to the switch to faricimab injections (59.6 ± 18 letters, Δ switch-6M = + 5; p = 0.007, Student’s t -test for paired samples; Fig. A), coupled with a reduction in CST (331 ± μm, Δ switch-6M = − 67.9 μm; p = 0.004, Student’s t -test for paired samples; Fig. B).

Techniques: